Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:52 UTC |
---|
Update Date | 2022-03-07 02:51:58 UTC |
---|
HMDB ID | HMDB0015416 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Fosamprenavir |
---|
Description | Fosamprenavir is only found in individuals that have used or taken this drug. It is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.Fosamprenavir is rapidly hydrolyzed to amprenavir by cellular phosphatases in the gut epithelium as it is absorbed. Amprenavir is an inhibitor of HIV-1 protease. During HIV replication, HIV protease cleaves viral polypeptide products of the Gag and Gag-Pol genes to form structural proteins of the virion core and essential viral enzymes. Amprenavir interferes with this process by binding to the active site of HIV-1 protease, thereby preventing the processing of viral Gag and Gag-Pol polyprotein precursors, resulting in the formation of immature non-infectious viral particles. |
---|
Structure | CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 |
---|
Synonyms | Value | Source |
---|
FOS-apv | ChEBI | (3-(((4-Aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester | HMDB | Fosamprenavir calcium | HMDB | VX175 CPD | HMDB | Lexiva | HMDB | GW908 CPD | HMDB | Fos-amprenavir | HMDB |
|
---|
Chemical Formula | C25H36N3O9PS |
---|
Average Molecular Weight | 585.607 |
---|
Monoisotopic Molecular Weight | 585.190986967 |
---|
IUPAC Name | {[(2R,3S)-1-[N-(2-methylpropyl)4-aminobenzenesulfonamido]-3-({[(3S)-oxolan-3-yloxy]carbonyl}amino)-4-phenylbutan-2-yl]oxy}phosphonic acid |
---|
Traditional Name | fosamprenavir |
---|
CAS Registry Number | 226700-79-4 |
---|
SMILES | CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 |
---|
InChI Identifier | InChI=1S/C25H36N3O9PS/c1-18(2)15-28(39(33,34)22-10-8-20(26)9-11-22)16-24(37-38(30,31)32)23(14-19-6-4-3-5-7-19)27-25(29)36-21-12-13-35-17-21/h3-11,18,21,23-24H,12-17,26H2,1-2H3,(H,27,29)(H2,30,31,32)/t21-,23-,24+/m0/s1 |
---|
InChI Key | MLBVMOWEQCZNCC-OEMFJLHTSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as aminobenzenesulfonamides. These are organic compounds containing a benzenesulfonamide moiety with an amine group attached to the benzene ring. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Benzenesulfonamides |
---|
Direct Parent | Aminobenzenesulfonamides |
---|
Alternative Parents | |
---|
Substituents | - Aminobenzenesulfonamide
- Phenylbutylamine
- Amphetamine or derivatives
- Benzenesulfonyl group
- Phosphoethanolamine
- Aniline or substituted anilines
- Monoalkyl phosphate
- Organic phosphoric acid derivative
- Phosphoric acid ester
- Organosulfonic acid amide
- Alkyl phosphate
- Organic sulfonic acid or derivatives
- Organosulfonic acid or derivatives
- Aminosulfonyl compound
- Tetrahydrofuran
- Sulfonyl
- Carboximidic acid derivative
- Dialkyl ether
- Ether
- Oxacycle
- Organoheterocyclic compound
- Organic 1,3-dipolar compound
- Propargyl-type 1,3-dipolar organic compound
- Organosulfur compound
- Organooxygen compound
- Organonitrogen compound
- Organopnictogen compound
- Organic oxide
- Hydrocarbon derivative
- Primary amine
- Amine
- Organic nitrogen compound
- Organic oxygen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.68 g/L | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Fosamprenavir,1TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4546.6 | Semi standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 3971.1 | Standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 6705.9 | Standard polar | 33892256 | Fosamprenavir,1TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4668.1 | Semi standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 3990.2 | Standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 6612.1 | Standard polar | 33892256 | Fosamprenavir,1TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4448.3 | Semi standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4007.5 | Standard non polar | 33892256 | Fosamprenavir,1TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 7151.2 | Standard polar | 33892256 | Fosamprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4456.4 | Semi standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4011.4 | Standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 6144.9 | Standard polar | 33892256 | Fosamprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4578.9 | Semi standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4045.0 | Standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5873.7 | Standard polar | 33892256 | Fosamprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4374.5 | Semi standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4058.8 | Standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 6387.6 | Standard polar | 33892256 | Fosamprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4504.3 | Semi standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4098.0 | Standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 6215.3 | Standard polar | 33892256 | Fosamprenavir,2TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4427.0 | Semi standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4092.0 | Standard non polar | 33892256 | Fosamprenavir,2TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 6203.5 | Standard polar | 33892256 | Fosamprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4520.9 | Semi standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4087.3 | Standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5327.6 | Standard polar | 33892256 | Fosamprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4330.8 | Semi standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4096.6 | Standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 5898.9 | Standard polar | 33892256 | Fosamprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4466.2 | Semi standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4136.4 | Standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5585.0 | Standard polar | 33892256 | Fosamprenavir,3TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4437.5 | Semi standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4138.6 | Standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 5549.3 | Standard polar | 33892256 | Fosamprenavir,3TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4350.9 | Semi standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4196.6 | Standard non polar | 33892256 | Fosamprenavir,3TMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 5834.0 | Standard polar | 33892256 | Fosamprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4450.8 | Semi standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 4175.6 | Standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C)C=C1 | 5090.4 | Standard polar | 33892256 | Fosamprenavir,4TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4468.3 | Semi standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4179.6 | Standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 5061.9 | Standard polar | 33892256 | Fosamprenavir,4TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4417.4 | Semi standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 4230.1 | Standard non polar | 33892256 | Fosamprenavir,4TMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C)S(=O)(=O)C1=CC=C(N([Si](C)(C)C)[Si](C)(C)C)C=C1 | 5276.6 | Standard polar | 33892256 | Fosamprenavir,1TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4749.6 | Semi standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4159.7 | Standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 6700.9 | Standard polar | 33892256 | Fosamprenavir,1TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4896.2 | Semi standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4204.4 | Standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 6542.2 | Standard polar | 33892256 | Fosamprenavir,1TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4704.6 | Semi standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4232.0 | Standard non polar | 33892256 | Fosamprenavir,1TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 7028.3 | Standard polar | 33892256 | Fosamprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4862.3 | Semi standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 4376.5 | Standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #1 | CC(C)CN(C[C@@H](OP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1 | 6158.3 | Standard polar | 33892256 | Fosamprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 5021.5 | Semi standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4436.4 | Standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #2 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 5875.1 | Standard polar | 33892256 | Fosamprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4814.3 | Semi standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 4464.5 | Standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #3 | CC(C)CN(C[C@@H](OP(=O)(O)O[Si](C)(C)C(C)(C)C)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N)C=C1 | 6316.4 | Standard polar | 33892256 | Fosamprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4961.9 | Semi standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 4525.9 | Standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #4 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)N(C(=O)O[C@H]1CCOC1)[Si](C)(C)C(C)(C)C)S(=O)(=O)C1=CC=C(N[Si](C)(C)C(C)(C)C)C=C1 | 6118.4 | Standard polar | 33892256 | Fosamprenavir,2TBDMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4889.6 | Semi standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 4504.8 | Standard non polar | 33892256 | Fosamprenavir,2TBDMS,isomer #5 | CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)C=C1 | 6077.8 | Standard polar | 33892256 |
|
---|
General References | - Wire MB, Shelton MJ, Studenberg S: Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet. 2006;45(2):137-68. [PubMed:16485915 ]
- Falcoz C, Jenkins JM, Bye C, Hardman TC, Kenney KB, Studenberg S, Fuder H, Prince WT: Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98. [PubMed:12162471 ]
- Wood R, Arasteh K, Stellbrink HJ, Teofilo E, Raffi F, Pollard RB, Eron J, Yeo J, Millard J, Wire MB, Naderer OJ: Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004 Jan;48(1):116-23. [PubMed:14693528 ]
- Furfine ES, Baker CT, Hale MR, Reynolds DJ, Salisbury JA, Searle AD, Studenberg SD, Todd D, Tung RD, Spaltenstein A: Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004 Mar;48(3):791-8. [PubMed:14982766 ]
- Sension M: Initial therapy for human immunodeficiency virus: broadening the options. HIV Clin Trials. 2004 Mar-Apr;5(2):99-111. [PubMed:15116286 ]
- Chapman TM, Plosker GL, Perry CM: Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs. 2004;64(18):2101-24. [PubMed:15341507 ]
- Hoffman RM, Umeh OC, Garris C, Givens N, Currier JS: Evaluation of sex differences of fosamprenavir (with and without ritonavir) in HIV-infected men and women. HIV Clin Trials. 2007 Nov-Dec;8(6):371-80. [PubMed:18042502 ]
- Smith KY, Weinberg WG, Dejesus E, Fischl MA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT: Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008 Mar 28;5:5. doi: 10.1186/1742-6405-5-5. [PubMed:18373851 ]
|
---|